Home › Funds › BRAIDWELL LP › GENB

BRAIDWELL LP position in GENB

GENERATE BIOMEDICINES INC · Health Care

BRAIDWELL LP reported holding 3,283,844 shares of GENB (GENERATE BIOMEDICINES INC) in its Q2 2026 13F filing — a position valued at US$55.4M, representing 2.18% of its reported portfolio and ranking #13 among its reported holdings. BRAIDWELL LP has disclosed GENB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)3.28M sh
Reported value held$55.40M
Portfolio Weight2.18%
First reportedQ1 2026
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BRAIDWELL LP's GENB position evolved

BRAIDWELL LP first disclosed a stake in GENB in Q1 2026 at 3,592,999 shares (US$44.9M). The position peaked in Q2 2026 at 3,283,844 shares, worth US$55.4M. Across 2 filings, BRAIDWELL LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,283,844 shares valued at US$55.4M — a reduction of -309,155 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 3.59M $44.91M New
Q2 2026 3.28M $55.40M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GENB and 13F data

GENB (GENERATE BIOMEDICINES INC) is a Health Care company. 96 other funds we track also report a position in GENB — the largest reported positions include Flagship Pioneering, LLC (US$1.06B), ARCH Venture Management, LLC (US$32.8M), HARBOURVEST PARTNERS LLC (US$29.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GENB

All GENB fund holders →

FAQ

How long has BRAIDWELL LP held GENB?

BRAIDWELL LP has disclosed GENB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is BRAIDWELL LP's current position in GENB?

As of Q2 2026, BRAIDWELL LP holds 3.28M shares of GENB (GENERATE BIOMEDICINES INC), valued at $55.40M, representing 2.18% of its reported portfolio and ranking #13.

Has BRAIDWELL LP been buying or selling GENB?

In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in GENB. The position peaked in Q2 2026 at 3.28M shares.

Which other funds hold GENB?

Other major institutional holders of GENB include Flagship Pioneering, LLC, ARCH Venture Management, LLC, HARBOURVEST PARTNERS LLC, among 96 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.